CORT News

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Robbins LLP Reminds CORT Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action

INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit– Hagens Berman

DEADLINE ALERT for PYPL, SMR, CORT, NAVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

Pomerantz LLP Reminds Shareholders with Losses on their Investment in Corcept Therapeutics Incorporated – CORT

CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders Have Opportunity to Lead Class Action Lawsuit!

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

CORT FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT